Enhanced photodynamic therapy of TiO2/N-succinyl-chitosan composite for killing cancer cells

Detalhes bibliográficos
Autor(a) principal: Ma, Min
Data de Publicação: 2022
Outros Autores: Cheng, Lu, Wang, Ling, Liang, Xing, Yang, LinJiao, Zhang, AiPing
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Brazilian Journal of Pharmaceutical Sciences
Texto Completo: https://www.revistas.usp.br/bjps/article/view/204490
Resumo: The aim of this study was to investigate the effect of TiO2/N-succinyl-chitosan composite (TiO2/ NSCS) photodynamic therapy (PDT), while considering the effects of various light sources on the activation of photosensitizer. The methyl thiazolyl tetrazolium assay was used to examine the cell survival rate of the cells. The results showed that glioma cell strain (U251) was the most sensitive cancer cell strain to TiO2/NSCS. When the concentration of TiO2/NSCS was between 0 and 800 μg·mL-1, there was no obvious cytotoxicity to normal liver cells (HL-7702) and U251 cells. During the PDT process, the photokilling effect of TiO2/NSCS on U251 cells under ultraviolet-A (UVA) light irradiation was stronger than that of pure TiO2, and its killing effects were positively correlated with concentration and irradiation time. In addition, both UVA and visible light could excite TiO2/ NSCS, which had significant killing effect on U251 cells. The results of acridine orange/ethidium bromide fluorescent double staining and Annexin V/propidium iodide double staining indicated that TiO2/NSCS under UVA and visible light irradiation could kill U251 cells by inducing apoptosis, and the apoptosis rate of TiO2/NSCS treatment groups was higher than that of TiO2 treatment groups. Therefore, TiO2/NSCS might be used as a potential photosensitizer in PDT.
id USP-31_d61f53e9891f82a8c65dd19b34b8795c
oai_identifier_str oai:revistas.usp.br:article/204490
network_acronym_str USP-31
network_name_str Brazilian Journal of Pharmaceutical Sciences
repository_id_str
spelling Enhanced photodynamic therapy of TiO2/N-succinyl-chitosan composite for killing cancer cellsPhotodynamic therapyTiO2/N-succinyl-chitosan compositeMethyl thiazolyl tetrazolium assayglioma cells (U251)Killing effectApoptosisThe aim of this study was to investigate the effect of TiO2/N-succinyl-chitosan composite (TiO2/ NSCS) photodynamic therapy (PDT), while considering the effects of various light sources on the activation of photosensitizer. The methyl thiazolyl tetrazolium assay was used to examine the cell survival rate of the cells. The results showed that glioma cell strain (U251) was the most sensitive cancer cell strain to TiO2/NSCS. When the concentration of TiO2/NSCS was between 0 and 800 μg·mL-1, there was no obvious cytotoxicity to normal liver cells (HL-7702) and U251 cells. During the PDT process, the photokilling effect of TiO2/NSCS on U251 cells under ultraviolet-A (UVA) light irradiation was stronger than that of pure TiO2, and its killing effects were positively correlated with concentration and irradiation time. In addition, both UVA and visible light could excite TiO2/ NSCS, which had significant killing effect on U251 cells. The results of acridine orange/ethidium bromide fluorescent double staining and Annexin V/propidium iodide double staining indicated that TiO2/NSCS under UVA and visible light irradiation could kill U251 cells by inducing apoptosis, and the apoptosis rate of TiO2/NSCS treatment groups was higher than that of TiO2 treatment groups. Therefore, TiO2/NSCS might be used as a potential photosensitizer in PDT.Universidade de São Paulo. Faculdade de Ciências Farmacêuticas2022-11-17info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/bjps/article/view/20449010.1590/s2175-97902022e181116Brazilian Journal of Pharmaceutical Sciences; Vol. 58 (2022)Brazilian Journal of Pharmaceutical Sciences; v. 58 (2022)Brazilian Journal of Pharmaceutical Sciences; Vol. 58 (2022)2175-97901984-8250reponame:Brazilian Journal of Pharmaceutical Sciencesinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/bjps/article/view/204490/194478Copyright (c) 2022 Brazilian Journal of Pharmaceutical Scienceshttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessMa, MinCheng, LuWang, LingLiang, XingYang, LinJiaoZhang, AiPing2023-05-25T14:11:04Zoai:revistas.usp.br:article/204490Revistahttps://www.revistas.usp.br/bjps/indexPUBhttps://old.scielo.br/oai/scielo-oai.phpbjps@usp.br||elizabeth.igne@gmail.com2175-97901984-8250opendoar:2023-05-25T14:11:04Brazilian Journal of Pharmaceutical Sciences - Universidade de São Paulo (USP)false
dc.title.none.fl_str_mv Enhanced photodynamic therapy of TiO2/N-succinyl-chitosan composite for killing cancer cells
title Enhanced photodynamic therapy of TiO2/N-succinyl-chitosan composite for killing cancer cells
spellingShingle Enhanced photodynamic therapy of TiO2/N-succinyl-chitosan composite for killing cancer cells
Ma, Min
Photodynamic therapy
TiO2/N-succinyl-chitosan composite
Methyl thiazolyl tetrazolium assay
glioma cells (U251)
Killing effect
Apoptosis
title_short Enhanced photodynamic therapy of TiO2/N-succinyl-chitosan composite for killing cancer cells
title_full Enhanced photodynamic therapy of TiO2/N-succinyl-chitosan composite for killing cancer cells
title_fullStr Enhanced photodynamic therapy of TiO2/N-succinyl-chitosan composite for killing cancer cells
title_full_unstemmed Enhanced photodynamic therapy of TiO2/N-succinyl-chitosan composite for killing cancer cells
title_sort Enhanced photodynamic therapy of TiO2/N-succinyl-chitosan composite for killing cancer cells
author Ma, Min
author_facet Ma, Min
Cheng, Lu
Wang, Ling
Liang, Xing
Yang, LinJiao
Zhang, AiPing
author_role author
author2 Cheng, Lu
Wang, Ling
Liang, Xing
Yang, LinJiao
Zhang, AiPing
author2_role author
author
author
author
author
dc.contributor.author.fl_str_mv Ma, Min
Cheng, Lu
Wang, Ling
Liang, Xing
Yang, LinJiao
Zhang, AiPing
dc.subject.por.fl_str_mv Photodynamic therapy
TiO2/N-succinyl-chitosan composite
Methyl thiazolyl tetrazolium assay
glioma cells (U251)
Killing effect
Apoptosis
topic Photodynamic therapy
TiO2/N-succinyl-chitosan composite
Methyl thiazolyl tetrazolium assay
glioma cells (U251)
Killing effect
Apoptosis
description The aim of this study was to investigate the effect of TiO2/N-succinyl-chitosan composite (TiO2/ NSCS) photodynamic therapy (PDT), while considering the effects of various light sources on the activation of photosensitizer. The methyl thiazolyl tetrazolium assay was used to examine the cell survival rate of the cells. The results showed that glioma cell strain (U251) was the most sensitive cancer cell strain to TiO2/NSCS. When the concentration of TiO2/NSCS was between 0 and 800 μg·mL-1, there was no obvious cytotoxicity to normal liver cells (HL-7702) and U251 cells. During the PDT process, the photokilling effect of TiO2/NSCS on U251 cells under ultraviolet-A (UVA) light irradiation was stronger than that of pure TiO2, and its killing effects were positively correlated with concentration and irradiation time. In addition, both UVA and visible light could excite TiO2/ NSCS, which had significant killing effect on U251 cells. The results of acridine orange/ethidium bromide fluorescent double staining and Annexin V/propidium iodide double staining indicated that TiO2/NSCS under UVA and visible light irradiation could kill U251 cells by inducing apoptosis, and the apoptosis rate of TiO2/NSCS treatment groups was higher than that of TiO2 treatment groups. Therefore, TiO2/NSCS might be used as a potential photosensitizer in PDT.
publishDate 2022
dc.date.none.fl_str_mv 2022-11-17
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.revistas.usp.br/bjps/article/view/204490
10.1590/s2175-97902022e181116
url https://www.revistas.usp.br/bjps/article/view/204490
identifier_str_mv 10.1590/s2175-97902022e181116
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://www.revistas.usp.br/bjps/article/view/204490/194478
dc.rights.driver.fl_str_mv Copyright (c) 2022 Brazilian Journal of Pharmaceutical Sciences
https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2022 Brazilian Journal of Pharmaceutical Sciences
https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidade de São Paulo. Faculdade de Ciências Farmacêuticas
publisher.none.fl_str_mv Universidade de São Paulo. Faculdade de Ciências Farmacêuticas
dc.source.none.fl_str_mv Brazilian Journal of Pharmaceutical Sciences; Vol. 58 (2022)
Brazilian Journal of Pharmaceutical Sciences; v. 58 (2022)
Brazilian Journal of Pharmaceutical Sciences; Vol. 58 (2022)
2175-9790
1984-8250
reponame:Brazilian Journal of Pharmaceutical Sciences
instname:Universidade de São Paulo (USP)
instacron:USP
instname_str Universidade de São Paulo (USP)
instacron_str USP
institution USP
reponame_str Brazilian Journal of Pharmaceutical Sciences
collection Brazilian Journal of Pharmaceutical Sciences
repository.name.fl_str_mv Brazilian Journal of Pharmaceutical Sciences - Universidade de São Paulo (USP)
repository.mail.fl_str_mv bjps@usp.br||elizabeth.igne@gmail.com
_version_ 1800222916074274816